Results 111 to 120 of about 88,229 (302)
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima +11 more
wiley +1 more source
RELIEVE: Revista Electrónica de Investigación y Evaluación Educativa, 2006 This report analyses the differential item functioning (DIF) in the Programme for Indicators of Student Achievement PISA2000. The items studied are coming from the Reading Comprehension Test.
Paula Elosua
doaj
Emerging Themes in Epidemiology, 2018 Background The use of meta-analysis to aggregate multiple studies has increased dramatically over the last 30 years. For meta-analysis of homogeneous data where the effect sizes for the studies contributing to the meta-analysis differ only by statistical
Lawrence M. Paul
doaj +1 more source
, 2006 POPULATION: Spinal cord injury (SCI) patients with neurogenic bladder have an increased risk for symptomatic urinary tract infection (UTI). Recurrent UTI requires multiple courses of antibiotic therapy, markedly increasing the incidence of multidrug ...
Bernard, Louis +6 more
core +1 more source
International Journal of Dermatology, EarlyView.ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao +26 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, EarlyView.We assessed four different doses of ME3183, a novel phosphodiesterase 4 inhibitor, and placebo in 132 patients with moderate to severe plaque psoriasis. At Week 16, more patients receiving ME3183 achieved ≥75% reduction in baseline Psoriasis Area and Severity Index scores than those receiving placebo, with no new safety concerns.
Kim A. Papp +5 more
wiley +1 more source
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
Journal of the European Academy of Dermatology and Venereology, EarlyView.In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui +15 more
wiley +1 more source
A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. [PDF]
, 2011 BackgroundRheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA).
Alfredsson, Lars +8 more
core
Journal of the European Academy of Dermatology and Venereology, EarlyView.Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer +10 more
wiley +1 more source